Royalty Pharma
2023–2024 federal contribution records · FEC Schedule A
01
Contribution summary
Loading the financial summary…
Reading the shared contribution publication for this cycle.
2023–2024 federal contribution records · FEC Schedule A
Loading the financial summary…
Reading the shared contribution publication for this cycle.
Federal contribution records grouped across normalized variants of this reported employer. Contributions are made by individuals, not by the employer.
Latest matching employer records · memo entries excluded from net amount
Read from indexed records .
Loading 10 contributions with dates…
Loading company overview…
These immutable labels appeared in FEC filings and are grouped under Royalty Pharma.
These totals and connections use all matching indexed employer records, keeping the latest version within that employer group and excluding memo entries from net amounts. Amendments that change the reported employer may affect this grouping. No profile rebuild is required.
Top 10 contributors and top 10 recipients · independent of list pagination
Explore the reported connections for Royalty Pharma. Contributor and recipient lists are available below.
Data: GovMoneyGraph, based on FEC records. Groupings and recipient-party allocations are derived analysis, not FEC-verified identities or party registrations. Read our contribution and classification methodology.
Reported name and ZIP groups; not verified unique people or cross-address identity matches · 10 per page
Showing 1–5 of 5 · largest absolute amount first
Reported name + ZIP cluster; not a verified identity merge · NEW YORK · NY · 10075 · ROYALTY PHARMA · CEO
DemocraticDerived from contributionsReported name + ZIP cluster; not a verified identity merge · MANHATTAN · NY · 10007 · ROYALTY PHARMA · BIOTECHNOLOGY
DemocraticDerived from contributionsReported name + ZIP cluster; not a verified identity merge · SPRING LAKE · NJ · 07762 · ROYALTY PHARMA · E.VP.
100% Republican · 0% unclassifiedDerived from contributionsReported name + ZIP cluster; not a verified identity merge · NORTH SALEM · NY · 10560 · ROYALTY PHARMA · INVESTOR
DemocraticDerived from contributionsReported name + ZIP cluster; not a verified identity merge · DURHAM · NC · 27703 · ROYALTY PHARMA · EXECUTIVE
98% Democratic · 2% unclassifiedDerived from contributionsWhere the contributions went · 10 per page
Showing 1–10 of 10 · largest absolute amount first
House campaign committee · SAG HARBOR · NY · AVLON, JOHN · U.S. House · NY · 01
DemocraticDerived from contributionsSenate campaign committee · HARTFORD · CT · MURPHY, CHRISTOPHER S · U.S. Senate · CT · 00
DemocraticDerived from contributionsPresidential campaign committee · PHILADELPHIA · PA · HARRIS, KAMALA · President · US · 00
DemocraticDerived from contributionsPAC (not qualified) · ALEXANDRIA · VA
100% Republican · 0% unclassifiedDerived from contributionsSenate campaign committee · FOXBORO · MA
DemocraticDerived from contributionsHouse campaign committee · RIDGEWOOD · NJ · GOTTHEIMER, JOSH · U.S. House · NJ · 05
DemocraticDerived from contributionsPAC with non-contribution account · WASHINGTON · DC
98% Democratic · 2% unclassifiedDerived from contributionsIndividual transactions · 10 per page
Dates below are the FEC-reported contribution dates, not filing or import dates. These are individual contributions grouped by the reported employer field, not contributions by a company.
Smallest contribution amounts first. Select Date of contribution or Amount to reverse the order.
| Date of contribution ↕ | Amount ↑ | Reported contributor / location | Recipient / filing |
|---|---|---|---|
| 2023-11-29FEC filing ↗ | $100 | COYNE, TERRANCEDURHAMNC27703EXECUTIVEROYALTY PHARMA | 314 ACTION IMPACT SLATEC00837021Primary (P)ATTRIBUTED TO JF BETWEEN UNDERWOOD, VARGAS, WILLIAMS, GOROFF, & 314 ACTION IMPACT SLATEFiling 1745396 |
| 2024-07-09FEC filing ↗ | $250 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Primary (P)CONTRIBUTION TO ACTBLUEFiling 1864088 · amended |
| 2024-07-06FEC filing ↗ | $330 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Primary (P)CONTRIBUTION TO ACTBLUEFiling 1864088 · amended |
| 2024-06-20FEC filing ↗ | $1,300 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Primary (P)EARMARKED FOR JOHN AVLON FOR CONGRESS (C00870568)Filing 1805179 |
| 2024-06-20FEC filing ↗ | $1,300 | URIST, MARSHALLNEW YORKNY10007DIRECTORROYALTY PHARMA | JOHN AVLON FOR CONGRESSC00870568Primary 2024 (P2024)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1850938 · amended |
| 2024-05-26FEC filing ↗ | $2,000 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Primary (P)EARMARKED FOR JOHN AVLON FOR CONGRESS (C00870568)Filing 1791562 |
| 2024-05-26FEC filing ↗ | $2,000 | URIST, MARSHALLNEW YORKNY10007BIOTECHNOLOGYROYALTY PHARMA | JOHN AVLON FOR CONGRESSC00870568Primary 2024 (P2024)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1794977 · amended |
| 2024-07-09FEC filing ↗ | $2,500 | URIST, MARSHALLNEW YORKNY10007DIRECTORROYALTY PHARMA | GILLIBRAND BALDWIN VICTORY FUNDC00833640Primary (P)Filing 1825650 |
| 2024-07-09FEC filing ↗ | $2,500 | URIST, MARSHALLMANHATTANNY10007BIOTECHNOLOGYROYALTY PHARMA | ACTBLUEC00401224Primary (P)EARMARKED FOR GILLIBRAND BALDWIN VICTORY FUND (C00833640)Filing 1864088 · amended |
| 2024-10-26FEC filing ↗ | $3,300 | KLYMKOWSKY, SARANORTH SALEMNY10560INVESTORROYALTY PHARMA | HARRIS FOR PRESIDENTC00703975General 2024 (G2024)* EARMARKED CONTRIBUTION: SEE BELOWFiling 1890563 · amended |
Refunds remain negative. Memo-only rows are marked and are not additional money. Latest versions are selected within matching employer records; amendments that change the employer may affect the grouping.
Open full contribution table →Industry classification summary
Royalty Pharma is identified as a specialty biopharmaceutical finance company that acquires royalty interests and provides funding to the industry. While it supports the pharmaceutical sector, its primary business model is investment and specialty finance, placing it in the Finance sector.
AI classification auto-approved under admin authorization
View source